Search
Indium In-111 chloride
go.drugbank.com/drugs/DB09490ApprovedIndium In-111 Chloride is a diagnostic radiopharmaceutical agent intended for radiolabeling OncoScint (satumomab pendetide) or ProstaScint (capromab pendetide) used for in vivo diagnostic imaging procedures and for radiolabeling Zevalin ...
Mixtures: Kit for the Preparation of Indium In 111 PentetreotideZongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigational[L53873,A274363] It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pathways while sparing wild-type epidermal growth factor receptor (EGFR), which … serves to limit associated toxicities.
Categories: Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitorsOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalApproximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsPropranolol
go.drugbank.com/drugs/DB00571ApprovedInvestigationalPropranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. … [L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Categories: Serotonin Receptor Antagonists, Serotonin 5-HT1 Receptor AntagonistsNadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigationalIt is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat. … The use of nadofaragene firadenovec provides a therapeutic alternative to patients seeking non-surgical alternatives for the treatment of BCG-unresponsive NMIBC.
Synonyms: TR-002, Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoterMirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its
Categories: Adrenergic beta-3 Receptor AgonistsProducts: MYRBETRIC® 50 MG TABLETAS DE LIBERACION PROLONGADA, MYRBETRIC® 25 MG TABLETAS DE LIBERACION PROLONGADAIndium In-111 oxyquinoline
go.drugbank.com/drugs/DB09473ApprovedThe degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. … Once inside, Indium detaches from the oxyquinoline complexes and becomes attached to cytoplasmic components.
Rhizopus stolonifer
go.drugbank.com/drugs/DB10814ApprovedRhizopus stolonifer is a fungus which can provoke allergic reactions. Rhizopus stolonifer extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureZilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition … [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigationalHepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. … It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.